Tinnitus UK Rates Lenire as Most Effective Treatment Option

"Neuromod welcomes Tinnitus UK's decision to recognise Lenire, and bimodal neuromodulation, as a safe and effective standard of care for tinnitus treatment," said Neuromod founding CEO, Dr. Ross O'Neill. "Millions of people in the UK and across Europe rely on Tinnitus UK for advice about treatment options and we are delighted that Neurmod's commitment to building compelling evidence is reflected in this new rating for Lenire." "Neuromod welcomes Tinnitus UK's decision to recognise Lenire, and...

DUBLIN, 05/11/2025 (informazione.news - comunicati stampa - salute e benessere)

 said Neuromod founding CEO, Dr. Ross O'Neill .

Lenire is a bimodal neuromodulation device which has been proven to provide long lasting relief from tinnitus. Lenire treats tinnitus through a combination of auditory and tongue stimulation that retrains the brain to significantly reduce tinnitus focus.

The device has been proven safe and effective with real world patients and across three large-scale clinical trials featuring more than 600 patients. Tinnitus UK's rating acknowledges Lenire's body of evidence according to Tinnitus UK CEO, Alex-Brooks Johnson .

 said Tinnitus UK CEO, Alex Brooks-Johnson .

Lenire's most recent clinical trial, TENT-A3, was a controlled clinical trial that was published in Nature Communications. TENT-A3 found Lenire was clinically superior to sound-only, the trial's control, for the majority of patients with bothersome tinnitus.

Results from Lenire's second large-scale clinical trial, TENT-A2, were published in Nature – Scientific Reports. TENT-A2 showed 95% of treatment compliant patients reported tinnitus improvement. 91% reported long-term relief that sustained for at least a year after treatment ended.

Analysis of 220 real world Lenire patients further validated Lenire's effectiveness as a tinnitus treatment device. The analysis, peer-reviewed and published in Nature Communications Medicine, showed that 91.5% of patients treated with Lenire had a clinically significant reduction in tinnitus after 12-weeks of treatment with Lenire.

said owner of Byrom Audiology and Tinnitus UK Advisory Board Member, Peter Byrom .

Lenire is exclusively available through hearing healthcare professionals across the United Kingdom , Europe , and the United States of America . Tinnitus patients who wish to be assessed for Lenire can find a specialised clinic at www.lenire.com/find-a-clinic/ .

Neuromod is a global medical technology company with offices in Ireland and the USA . The company specializes in the design and development of neuromodulation technologies to address the clinical needs of tinnitus patients.

Neuromod has completed extensive clinical trials to confirm the safety and effectiveness of its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire. 

For more information about Neuromod visit .

Tinnitus UK, an independent charity dedicated to providing information and support for individuals living with tinnitus in the United Kingdom , plays a crucial role in enhancing the quality of life for those affected by this condition.

The charity strives to facilitate improved well-being through a variety of support avenues, including online and in-person support groups, a helpline featuring a chatbot and live webchat, and an informative website.

Tinnitus UK, receives no direct government funding and is committed to educating both medical professionals and the wider community about tinnitus, advocating prevention, and working towards finding a cure.

 

Tinnitus is commonly known as 'ringing in the ears'. It is a complex neurological condition that causes a perception of sound when there is no external source. It is estimated that 15% of the global adult population is living with tinnitus.

Photo - https://mma.prnewswire.com/media/2813427/Tinnitus_UK_CEO.jpg

View original content:https://www.prnewswire.co.uk/news-releases/tinnitus-uk-rates-lenire-as-most-effective-treatment-option-302604393.html